Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors.
Francesco CucciaRosario MazzolaVanessa FigliaNiccolò Giaj-LevraLuca NicosiaFrancesco RicchettiMichele RigoGiorgio AttinàClaudio VitaleEdoardo PastorelloRuggero RuggieriFilippo AlongiPublished in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2022)
= 105 Gy (range 96-180 Gy). Median follow-up was 29.5 months (range 6-81), with no acute or late G > 2 adverse event. Our LC rates at 2 and 4 years were 92.4 and 89.8%, respectively. DPFS rates at 2 and 4 years were 45.3 and 27.2%, respectively. A second SBRT course was proposed in 21 patients (29.5%) who developed an oligoprogression, resulting in median time to second progression of 9 months (range 2-44) and 2‑year PFS2 rate of 42.4%. At univariate analysis, patients with sequential oligometastases reported better OS rates (p = 0.002), which was also confirmed at multivariate analysis, where distant progression was also related to worse OS (p = 0.022). Higher local control rates relate to better PFS (p = 0.04). The 2‑ and 4‑year OS rates were 61 and 39.7% CONCLUSION: SBRT is feasible for pulmonary oligometastases with favorable outcomes and toxicity. At multivariate analysis, patients with sequential oligometastatic progression maintain a survival advantage. Also, local control was found to be related to improved PFS rates.
Keyphrases
- prognostic factors
- radiation therapy
- early stage
- squamous cell carcinoma
- risk assessment
- mass spectrometry
- intensive care unit
- data analysis
- liver failure
- adipose tissue
- skeletal muscle
- hepatitis b virus
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- electronic health record
- solid phase extraction